Eylea and Avastin are two drugs currently in high demand for treating ocular diseases. They fundamentally block the growth of abnormal blood vessels, but they differ in FDA approval, cost, and treatment frequency.
What Are Eylea and Avastin?
Eylea (aflibercept) is an FDA-approved medication, especially for eye conditions. It works by inhibiting two proteins, VEGF and PlGF, leading to abnormal blood vessel growth in the eye. It has been approved for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.
Avastin is a medication developed for the treatment of cancer. Ophthalmologists use it off-label for treating disorders of the retina. Similar to Eylea, Avastin works by blocking VEGF to prevent abnormal blood vessel growth. Though not FDA-approved for eye use, it has proven effective in clinical practice.
Key Differences between Eylea and Avastin
-
FDA Approval Status
Eylea is FDA-approved for the treatment of retinal diseases. That means it has undergone extensive clinical testing for conditions affecting the eyes. Avastin has FDA approval for cancer treatment. However, it is also used rather frequently off-label in ophthalmology. Ophthalmologists have used Avastin for years, and it is effective.
-
How They Work
Both medications target VEGF, but Eylea has a more advanced mechanism. Eylea blocks both VEGF and PlGF through a decoy receptor system. This dual action often results in longer efficacy. Avastin acts only on VEGF-A, which may require more frequent treatments.
-
Treatment Frequency
Eylea allows for longer injection intervals than Avastin. Patients receiving Eylea usually receive injections every 8-12 weeks after initial loading doses. Injections with Avastin typically occur every 4 weeks. Clinical trials reported that Avastin patients received, on average, more injections (8.7) than Eylea patients (7.2).
-
Cost Comparison
This, in fact, is the most significant difference between these two treatments. In the United States, Eylea costs approximately $1,850-$2,000 per injection, while Avastin costs around $50-$60 per injection. The vast price difference makes Avastin considerably more accessible for many patients.
Which One is More Effective?
-
For Diabetic Macular Edema
According to an NIH-funded clinical trial, Eylea outperformed Avastin in DME patients with vision of 20/50 or worse. After 2 years, all groups showed improvement in visual acuity, with Eylea demonstrating a clear advantage over Avastin in this specific patient population. Nonetheless, both treatments significantly improved vision.
-
For Wet AMD and Retinal Vein Occlusion
Numerous studies have shown that Eylea and Avastin are effective in treating wet AMD. They differ mainly in treatment intervals and convenience. Recent research has found that Avastin is as effective as Eylea for treating central retinal vein occlusion. An anti-VEGF injection has resulted in significant vision improvement in 45-55% of patients with RVO.
Side Effects and Safety
-
Common Side Effects
Common side effects are similar for both treatments. There is mild eye pain, redness, and blurred vision, often temporary. Other shared side effects include increased intraocular pressure and the feeling of something in the eye.
-
Serious Side Effects
Eylea might have a slightly increased risk for eye inflammation. Serious, though rare, complications include endophthalmitis, an infection of the eye, and a detached retina. Avastin has a marginally higher risk of systemic complications like stroke or heart attack in susceptible patients. Both drugs can increase the risk of blood clots.
Which Treatment is Appropriate for Whom?
-
When Eylea Is Indicated
It is suitable for patients who prefer fewer injections and longer treatment intervals. Eylea is indicated for patients with moderate to severe vision loss from DME. It benefits patients who are concerned about systemic side effects. This choice is very often influenced by insurance coverage and prior authorization.
-
When Avastin Is Preferred
Avastin is ideal for cost-conscious patients or those without good insurance coverage. Most insurance plans require a trial of Avastin before approving Eylea. It remains effective for wet AMD and other retinal conditions that require its use. Avastin is also available in most developing countries because of its affordability.
Making the Right Choice for Your Eyes
Choosing between Eylea and Avastin will depend on various factors. Your eye specialist will take into account your specific condition, the extent of your vision loss, and your treatment goals. Insurance coverage and cost clearly play a decisive factor in most considerations. Both treatments have been proven in the management of retinal diseases.
For more information on treatments such as Eylea and Avastin, visit RVAF. With our specialists’ expertise, you will take the right path toward protecting and restoring your vision. Call today to schedule your consultation and take that first step to clearer, healthier eyesight!